IRIS Institutional Research Information System - OPENBS Open Archive UniBS

Tomasoni, Daniela
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.946
NA - Nord America 2.782
EU - Europa 1.519
SA - Sud America 873
AF - Africa 75
OC - Oceania 5
Totale 8.200
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.678
SG - Singapore 1.154
BR - Brasile 755
CN - Cina 591
HK - Hong Kong 530
IT - Italia 367
DE - Germania 302
VN - Vietnam 251
FI - Finlandia 162
RU - Federazione Russa 157
GB - Regno Unito 135
TR - Turchia 133
IN - India 73
IE - Irlanda 69
UA - Ucraina 59
AR - Argentina 51
BD - Bangladesh 51
CA - Canada 44
MX - Messico 40
FR - Francia 39
CZ - Repubblica Ceca 35
ZA - Sudafrica 34
NL - Olanda 33
PL - Polonia 33
JP - Giappone 30
SE - Svezia 29
IQ - Iraq 28
AT - Austria 25
ES - Italia 22
EC - Ecuador 17
PK - Pakistan 17
SA - Arabia Saudita 17
CO - Colombia 12
MA - Marocco 12
ID - Indonesia 11
VE - Venezuela 11
KE - Kenya 10
PE - Perù 10
AE - Emirati Arabi Uniti 9
EG - Egitto 9
BE - Belgio 8
LT - Lituania 8
TN - Tunisia 7
UZ - Uzbekistan 7
BG - Bulgaria 6
PH - Filippine 6
PY - Paraguay 6
LV - Lettonia 5
NP - Nepal 5
TT - Trinidad e Tobago 5
AZ - Azerbaigian 4
CH - Svizzera 4
PA - Panama 4
UY - Uruguay 4
BO - Bolivia 3
DO - Repubblica Dominicana 3
JM - Giamaica 3
JO - Giordania 3
KZ - Kazakistan 3
LA - Repubblica Popolare Democratica del Laos 3
NO - Norvegia 3
NZ - Nuova Zelanda 3
PT - Portogallo 3
AU - Australia 2
CL - Cile 2
GY - Guiana 2
HN - Honduras 2
HR - Croazia 2
IL - Israele 2
KG - Kirghizistan 2
LB - Libano 2
MK - Macedonia 2
PS - Palestinian Territory 2
RO - Romania 2
RS - Serbia 2
SY - Repubblica araba siriana 2
AL - Albania 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
BY - Bielorussia 1
CY - Cipro 1
DM - Dominica 1
DZ - Algeria 1
EE - Estonia 1
ET - Etiopia 1
GR - Grecia 1
IS - Islanda 1
KH - Cambogia 1
KW - Kuwait 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MM - Myanmar 1
MN - Mongolia 1
MY - Malesia 1
OM - Oman 1
SN - Senegal 1
SV - El Salvador 1
TM - Turkmenistan 1
Totale 8.200
Salva come PNG Salva come JPEG
Città #
Hong Kong 528
Singapore 514
Ashburn 362
Beijing 243
Los Angeles 149
New York 142
Chandler 138
The Dalles 125
Helsinki 116
Istanbul 113
Munich 106
Fairfield 102
Dallas 95
Ho Chi Minh City 92
Princeton 75
São Paulo 71
Dublin 69
Redondo Beach 61
Moscow 58
Buffalo 57
Frankfurt am Main 57
Milan 55
Romola 55
Chicago 52
Hanoi 49
Houston 47
San Francisco 43
Shanghai 40
Woodbridge 40
Wilmington 35
Seattle 34
Cambridge 32
Brescia 27
Jacksonville 27
Brno 26
London 26
Tokyo 26
Boston 24
Brooklyn 24
Turku 24
Warsaw 24
Montreal 23
Santa Clara 23
Ann Arbor 22
Orem 21
Atlanta 20
Haiphong 18
Lappeenranta 18
Nuremberg 18
Poplar 18
Belo Horizonte 17
Stockholm 17
Denver 16
Düsseldorf 16
Johannesburg 16
Brasília 15
Washington 15
Chennai 14
Porto Alegre 14
Rio de Janeiro 14
Rome 14
Guangzhou 13
Kilburn 12
Phoenix 12
Toronto 12
Curitiba 11
Salvador 11
Vienna 11
Amsterdam 10
Baghdad 10
Buenos Aires 10
Charlotte 10
City of London 10
Mumbai 10
Querétaro 10
Ankara 9
Campinas 9
Da Nang 9
Dhaka 9
Erbil 9
Manchester 9
Mexico City 9
Trieste 9
Biên Hòa 8
Brussels 8
Cape Town 8
Changsha 8
Kyiv 8
Nairobi 8
Newark 8
Salt Lake City 8
Guayaquil 7
Lima 7
Maringá 7
Pune 7
Thái Bình 7
Turin 7
Caxias do Sul 6
Fortaleza 6
Hortolândia 6
Totale 4.680
Salva come PNG Salva come JPEG
Nome #
August 2020 at a glance: focus on neurohormonal antagonists and electrolytes 139
Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy 138
Acute heart failure: More questions than answers 117
Association of Troponin Levels With Mortality in Italian Patients Hospitalized With Coronavirus Disease 2019: Results of a Multicenter Study 117
Clinical characteristics and outcome of acute heart failure patients with mid-range ejection fraction. 107
Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19) 103
In-hospital and long-term mortality for acute heart failure: analysis at the time of admission to the emergency department 99
Highlights in heart failure 98
Review: Evidence-Based Management of Acute Heart Failure 98
COVID 19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease 94
Adherence and optimization of angiotensin converting enzyme inhibitor/angiotensin II receptors blockers and beta-blockers in patients hospitalized for acute heart failure 88
The prognostic value of serial troponin measurements in patients admitted for COVID-19 88
Machine learning for prediction of in-hospital mortality in coronavirus disease 2019 patients: results from an Italian multicenter study 87
Combined Role of Troponin and Natriuretic Peptides Measurements in Patients With Covid-19 (from the Cardio-COVID-Italy Multicenter Study) 87
Congestion in Patients with Advanced Heart Failure: Assessment and Treatment 86
Prediction of mortality and heart failure hospitalisations in patients undergoing M-TEER: external validation of the COAPT risk score 86
2024 update in heart failure 85
Changes in Right Ventricular-to-Pulmonary Artery Coupling After Transcatheter Edge-to-Edge Repair in Secondary Mitral Regurgitation 83
Pulmonary embolism in patients with COVID-19: characteristics and outcomes in the Cardio-COVID Italy multicenter study 82
Implications of atrial fibrillation on the clinical course and outcomes of hospitalized COVID-19 patients: results of the Cardio-COVID-Italy multicentre study 81
Advanced heart failure: guideline-directed medical therapy, diuretics, inotropes, and palliative care 81
Prevalence and clinical outcomes of isolated or combined moderate to severe mitral and tricuspid regurgitation in patients with cardiac amyloidosis 76
Telemedicine for the treatment of heart failure: new opportunities after COVID-19 76
Echocardiographic findings in subjects with an amyloidogenic apolipoprotein A1 pathogenic variant 76
Left ventricular wall thickness and severity of cardiac disease in women and men with transthyretin amyloidosis 76
Medical therapy of cardiogenic shock: Contemporary use of inotropes and vasopressors 75
Sex-related differences in patients with coronavirus disease 2019: results of the Cardio-COVID-Italy multicentre study 75
Right ventricular to pulmonary artery coupling and outcome in patients with cardiac amyloidosis 74
Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID-19. Results of the Cardio-COVID-Italy multicentre study 74
Prognostic significance of serum potassium in patients hospitalized for acute heart failure 72
[Empagliflozin and heart failure: the EMPEROR-Reduced trial] 72
COVID-19 and Heart Failure: From Epidemiology During the Pandemic to Myocardial Injury, Myocarditis, and Heart Failure Sequelae 72
[Transcatheter devices for chronic heart failure: state of the art] 72
Updates in heart failure: sodium glucose co-transporter 2 inhibitors and beyond - major changes are coming 72
Determinants of the protective effect of glucocorticoids on mortality in hospitalized patients with COVID-19: Insights from the Cardio-COVID-Italy multicenter study 70
September 2020 at a glance: focus on heart failure with preserved ejection fraction and medical therapy 70
[Sodium-glucose cotransporter 2 inhibitors and heart failure with preserved ejection fraction: the EMPEROR-Preserved and DELIVER studies] 69
Impact on clinical outcomes of right ventricular response to percutaneous correction of secondary mitral regurgitation 69
Cardiac contractility modulation: an effective treatment strategy for heart failure beyond reduced left ventricular ejection fraction? 67
A year in heart failure: an update of recent findings 67
Sodium glucose co-transporter 2 inhibitors and quality of life in patients with heart failure: a comprehensive systematic review and meta-analysis of randomized controlled trials 67
July 2020 at a glance: focus on imaging and cardiomyopathies 67
Prognostic value of right ventricular longitudinal strain in patients with secondary mitral regurgitation undergoing transcatheter edge-to-edge mitral valve repair 66
August 2021 at a glance: focus on cardiomyopathies, medical treatment and devices 66
Direct Oral Anticoagulants for the Treatment of Left Ventricular Thrombus-A New Indication? A Meta-summary of Case Reports. 66
Characteristics and outcomes of patients with tricuspid regurgitation and advanced heart failure 65
April 2022 at a glance: focus on prevention, acute heart failure and heart failure with preserved ejection fraction 65
Impact of Transcatheter Edge-to-Edge Mitral Valve Repair on Guideline-Directed Medical Therapy Uptitration 65
Impact of COVID-2019 outbreak on prevalence, clinical presentation and outcomes of ST-elevation myocardial infarction 65
2023 focused update of the 2021 ESC heart failure guidelines: Key messages for clinical practice 65
Heart failure in the last year: progress and perspective 64
How to tackle therapeutic inertia in heart failure with reduced ejection fraction. A scientific statement of the Heart Failure Association of the ESC 62
Heart failure: an update from the last years and a look at the near future 62
Aiming at harmony. Comparing and contrasting International HFrEF Guidelines 61
Evolution of tricuspid regurgitation after transcatheter edge-to-edge mitral valve repair for secondary mitral regurgitation and its impact on mortality 61
Obesity, heart failure with preserved ejection fraction, and the role of glucagon-like peptide-1 receptor agonists 61
Pre-discharge and early post-discharge management of patients hospitalized for acute heart failure: A scientific statement by the Heart Failure Association of the ESC 61
Characteristics, treatment, and outcomes of early vs. late enrollees of the STRONG-HF trial 59
Value of the HFA-PEFF and H2 FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis 58
Coronavirus disease 2019 and cardiovascular disease: what we have learnt during the last 2 years 58
[Diagnostic-therapeutic care pathways for patients with cardiac amyloidosis - SIC/ANMCO Consensus document. Edited by the Italian Cardiac Amyloidosis Network (RIAC)] 58
August 2022 at a glance: focus on heart failure with preserved ejection fraction and cardiac amyloidosis 58
Impact and predictors of device-related thrombus after percutaneous left atrial appendage closure 58
Frailty according to the 2019 HFA-ESC definition in patients at risk for advanced heart failure: Insights from the HELP-HF registry 57
Sacubitril/valsartan in real-life European patients with heart failure and reduced ejection fraction: a systematic review and meta-analysis 56
April 2023 at a glance: focus on diagnosis and comorbidities 55
Impact of malnutrition in patients with severe heart failure 55
Clinical and prognostic implications of heart failure hospitalization in patients with advanced heart failure 54
Biologically active adrenomedullin as a marker for residual congestion and early rehospitalization in patients hospitalized for acute heart failure: Data from STRONG-HF 54
Myocardial Involvement in COVID-19: an Interaction Between Comorbidities and Heart Failure with Preserved Ejection Fraction. A Further Indication of the Role of Inflammation 53
The Mayo ATTR-CM score versus other diagnostic scores and cardiac biomarkers in patients with suspected cardiac amyloidosis 53
Prognostic impact of the updated 2018 HFA-ESC definition of advanced heart failure: results from the HELP-HF registry 53
Clinical burden and predictors of non-cardiovascular mortality and morbidity in advanced heart failure 53
Ischemic Etiology in Advanced Heart Failure: Insight from the HELP-HF Registry 53
Treating amyloid transthyretin cardiomyopathy: lessons learned from clinical trials 52
Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the AC-TIVE study, an Italian nationwide survey 52
Impact of Pulmonary Hypertension on Outcomes after Transcatheter Tricuspid Valve Edge-to-Edge Repair 51
Multimodality imaging in the diagnostic management of concomitant aortic stenosis and transthyretin-related wild-type cardiac amyloidosis 51
Predicting survival in patients with severe heart failure: Risk score validation in the HELP-HF cohort 51
Contemporary Drug Treatment of Advanced Heart Failure with Reduced Ejection Fraction 49
Coronary artery disease: novel insights in a long-standing disease 49
Addressing comorbidities in heart failure: When feeling better and living longer go in the same direction 48
Device-based percutaneous treatments to decompress the left atrium in heart failure with preserved ejection fraction 48
Detailed Assessment of the "I Need Help" Criteria in Patients With Heart Failure: Insights From the HELP-HF Registry 47
March 2023 at a glance: pathophysiology, medical therapy and devices 47
Guideline-directed medical therapy in severe heart failure with reduced ejection fraction: an analysis from the HELP-HF registry 47
Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM-AHF trial 47
Blood pressure and intensive treatment up-titration after acute heart failure hospitalization: Insights from the STRONG-HF trial 47
January 2023 at a glance: focus on acute heart failure and medical therapy 47
Renin-angiotensin-aldosterone inhibitors and COVID-19: nearing the end of a media-fuelled controversy 47
December 2020 at a glance: focus on COVID-19, comorbidities and palliative care 46
Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology 46
January 2022 at a glance: time for the new ESC guidelines on heart failure 45
NT-proBNP and high-intensity care for acute heart failure: the STRONG-HF trial 45
November 2021 at a glance: focus on prevention, comorbidities, cardiogenic shock and novel devices 44
Titration of Medications After Acute Heart Failure Is Safe, Tolerated, and Effective Regardless of Risk 44
Optimization of Evidence-Based Heart Failure Medications After an Acute Heart Failure Admission: A Secondary Analysis of the STRONG-HF Randomized Clinical Trial 44
Changes in Liver Function Tests, Congestion, and Prognosis After Acute Heart Failure: The STRONG-HF Trial 44
October 2022 at a glance: focus on clinical trials 43
Tailored therapies for patients affected by systemic sclerosis with primary heart involvement: The role of rituximab 43
Totale 6.676
Salva come PNG Salva come JPEG
Categoria #
all - tutte 63.317
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 63.317
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021271 0 0 0 0 0 20 89 68 20 38 21 15
2021/2022202 4 41 4 6 8 6 8 10 14 10 18 73
2022/2023486 59 36 8 18 36 137 7 32 73 15 31 34
2023/20241.152 59 13 106 90 74 136 82 23 278 38 43 210
2024/20252.595 21 28 95 247 247 229 283 124 212 271 486 352
2025/20263.505 567 767 480 871 502 318 0 0 0 0 0 0
Totale 8.317